Systemic juvenile xanthogranuloma has a higher frequency of ALK translocations than <i>BRAFV600E</i> mutations
Jiaosheng Xu,Xin Huang,Yang Wen,Zenggang Pan,Hongyun Lian,Mutong Zhao,Min Li,Zejun Duan,Yanping Zhang,Gaolei Zhang,Xueling Qi,Jianping Tang,Zigang Xu,Zifen Gao,Libing Fu,Lin Ma
DOI: https://doi.org/10.1016/j.jaad.2020.08.053
IF: 15.487
2023-01-01
Journal of the American Academy of Dermatology
Abstract:To the Editor: Juvenile xanthogranuloma (JXG), the most common type of non-Langerhans cell histiocytosis (non-LCH), is generally confined to skin (cutaneous JXG [CJXG]) in children during the first 3 years of life.1Janssen D. Harms D. Juvenile xanthogranuloma in childhood and adolescence: a clinicopathologic study of 129 patients from the kiel pediatric tumor registry.Am J Surg Pathol. 2005; 29: 21-28Crossref PubMed Scopus (273) Google Scholar Rarely, JXG involves extracutaneous tissues or systemic organs (SJXG), resulting in higher morbidity and mortality. Activated mitogen activated protein kinase (MAPK) pathway mutations and anaplastic lymphoma kinase (ALK) translocations have been increasingly detected in subsets of histiocytosis,2Durham B.H. Lopez Rodrigo E. Picarsic J. et al.Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.Nat Med. 2019; 25: 1839-1842Crossref PubMed Scopus (82) Google Scholar but such data regarding molecular alterations in Chinese patients with JXG are lacking. We therefore retrospectively reviewed 456 pediatric patients with biopsy specimen-confirmed JXG to investigate BRAFV600E mutations and ALK translocations via digital drop polymerase chain reaction and in situ hybridization, respectively. Organ involvement in patients with SJXG was evaluated according to previously described LCH methodologies.3Haupt R. Minkov M. Astigarraga I. et al.Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years.Pediatr Blood Cancer. 2013; 60: 175-184Crossref PubMed Scopus (404) Google Scholar The 23 patients (5%) with SJXG presented a 1.9:1 male-to-female ratio and median age of onset at 16 months, similar to the 433 patients (95%) with CJXG (Table I). Cutaneous lesions were present in 15 patients (65.2%) with SJXG. Compared with CJXG, patients with SJXG mostly had multiple papules or nodules (n = 10; Supplementary Fig 1, available via Mendeley at https://doi.org/10.17632/528zps82wh.1), often extending to ≥2 locations, or giant skin masses (n = 3). The most common extracutaneous sites included the central nervous system (n = 11), liver (n = 9), lungs (n = 8; Supplementary Fig 2), kidney (n = 5), and hematologic involvement (n = 5; Table II). Four patients (17.4%) with SJXG died of the disease or complications.Table IComparison of systemic juvenile xanthogranuloma (SJXG) and cutaneous juvenile xanthogranuloma (CJXG)Variable∗Data are presented as the number of patients or as the median (interquartile range).CJXG (n = 433)SJXG (n = 23)P value†Based on Mann-Whitney tests for continuous variables and the Fisher exact test for categorical variables.Sex.826 Male24915 Female1848Age, mo‡Age of onset.16 (8-36)13 (4-48).594Skin lesion Solitary3132<.001 Multiple8710.015 Giant (>2 cm)333.413Locations of skin lesion Head and neck1921<.001 Trunk1122.064 Extremities782.397 ≥2 locations5110<.001Onset of skin lesion… Before systemic…3 After systemic…1 Concomitant…11BRAFV600E.002 Mutation04 Wild-type8419ALK translocation<.001 Positive08 Negative8415∗ Data are presented as the number of patients or as the median (interquartile range).† Based on Mann-Whitney tests for continuous variables and the Fisher exact test for categorical variables.‡ Age of onset. Open table in a new tab Table IICharacteristics of systemic juvenile xanthogranulomaSex/age∗Age of onset., moInitial clinical presentationsSitesALK translocation/BRAFV600E mutationTreatment/responseOutcome/duration, moF/3Solitary subcutaneous mass, ADOmentum, mesenterium, peritoneum, abdomen wallNegative/wild-typeSE/CRDF/10F/11Scattered skin nodules, DISkin, CNS, lungPositive/wild-typeCT/CRDF/26F/4Multiple skin macules and nodulesSkin, eye, liver, lung, kidney, CNSPositive/wild-typeCT/NRDOD/12F/2Fever, thrombocytopeniaSkin, liver, HI, kidney, spleenNegative/wild-typeMS/PRAWD/63M/69Pallor, AD, abdominalgiaHI, lung, liver, kidney, testicle, eye, pancreas, parotid glandPositive/wild-typeCT/CRDF/20M/at birthSolitary giant skin mass (>2 cm), thrombocytopeniaSkin, HI, liver, spleen, Lymph nodeNegative/wild-typeMS, SE/NRDOD/6M/16Fever, pancytopenia, ADHI, liver, spleen, skinNegative/wild-typeCT/NRDOH/6F/68Fever, cough, severe dyspneaLung, liver, CNS, skinPositive/wild-typeCT/PRAWD/35F/42Failure to thrive, blurred visionCNS, eyeNegative/positiveSE/PRAWD/65M/127Paralysis of both legsIntraspine (T9-T10)Negative/wild-typeSE/CRDF/2M/13Fever, pancytopenia, ADHI, BM, liver, spleen, kidneyPositive/wild-typeCT/NRDOH/6M/at birthMultiple skin nodules, giant skin massSkin, liver, lung, CNS, kidneyNegative/wild-typeMS/PRAWD/18M/13Multiple skin nodules, giant skin massSkin, cranium, lung, eyeNegative/wild-typeCT/PRAWD/15M/12Weakness, cough, feverLung, skin, pancreas, testicle, parotid glandPositive/wild-typeCT/PRAWD/14M/48HeadacheCNS, skin, craniumNegative/positiveSE/CRDF/72M/60Generalized skin nodules, DI, lamenessSkin, CNSNegative/wild-typeCT/PRAWD/105M/110Fever, vomiting, abdominaliaOmentum, mesenterium, peritoneumPositive/wild-typeCT/PRAWD/10M/18Cough, feverLung, mediastinal lymph nodesNegative/wild-typeST/SRAWD/19F/60HeadacheCNSPositive/wild-typeSE/CRDF/4F/44Multiple skin nodules, DI, orbital massCNS, cranium, skinNegative/positiveCT/PRAWD/2M/45DICNS, liver, spleen, skinNegative/positiveCT, vemurafenib/PRAWD/23M/at birthMultiple skin nodules, glaucomaSkin, eye, testicleNegative/wild-typeMS/PRAWD/10M/5Multiple skin nodules, scleral massSkin, eyeNegative/wild-typeObservation/SRAWD/13AD, Abdominal distention; AWD, alive with disease; BM, bone marrow; CT, chemotherapy; CNS, central nervous system; CR, complete response; DF, disease free; DI, diabetes insipidus; DOD, died of disease; DOH, died of hemophagocytic histiocytosis; F, female; HI, hematologic involvement; M, male; MS, monosteroid therapy; NR, no response; PR, partial response; SE, surgical excision; SR, spontaneous regression; ST, symptomatic therapy.∗ Age of onset. Open table in a new tab AD, Abdominal distention; AWD, alive with disease; BM, bone marrow; CT, chemotherapy; CNS, central nervous system; CR, complete response; DF, disease free; DI, diabetes insipidus; DOD, died of disease; DOH, died of hemophagocytic histiocytosis; F, female; HI, hematologic involvement; M, male; MS, monosteroid therapy; NR, no response; PR, partial response; SE, surgical excision; SR, spontaneous regression; ST, symptomatic therapy. Molecular alternations were present in 12 patients (52.2%) with SJXG, including 8 (34.8%) with ALK translocations and 4 (17.4%) with BRAFV600E mutations. ALK translocations and BRAFV600E mutations were mutually exclusive. Of 11 patients with central nervous system involvement, 8 (72.7%) displayed molecular alterations (4 with ALK translocation; 4 with BRAFV600E mutation), and 5 of 8 patients with lung involvement (62.5%) harbored an ALK translocation. As a control, no patients with SJXG from 2015 to 2016 (n = 84) exhibited these molecular alterations. Immunostaining for ALK and BRAFV600E supported the genetic findings. An ALK translocation occurred in 50% (2 of 4) of patients who died. SJXG and CJXG showed significant molecular differences, consistent with previous reports, but a few cases of CJXG with genetic aberrations were reported elsewhere.2Durham B.H. Lopez Rodrigo E. Picarsic J. et al.Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.Nat Med. 2019; 25: 1839-1842Crossref PubMed Scopus (82) Google Scholar These molecular alterations may be associated with systemic involvement in SJXG differently from CJXG. In SJXG, frequent ALK expression and infrequent BRAFV600E mutations were detected compared with previous reports. Recurrent ALK expression suggests a novel pathogenesis of histiocytic proliferation in SJXG. BRAFV600E mutations play a crucial role in the pathogenesis of SJXG with central nervous system involvement. Some lesions with clinical and histopathologic similarities to JXG have been considered as Erdheim-Chester disease, a rare non-LCH characterized by xanthogranulomatous infiltration of multiple organs, with activated MAPK pathway mutations, including BRAFV600E.4Emile J.F. Abla O. Fraitag S. et al.Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.Blood. 2016; 127: 2672-2681Crossref PubMed Scopus (798) Google Scholar ALK-positive histiocytosis has been proposed and shows considerable overlap with SJXG with ALK expression.5Chang K.T.E. Tay A.Z.E. Kuick C.H. et al.ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion.Mod Pathol. 2019; 32: 598-608Abstract Full Text Full Text PDF PubMed Scopus (57) Google Scholar Such patients share systemic involvement and may benefit from therapies targeted toward pathogenic molecular alterations. We treated a patient with BRAFV600E-mutant SJXG with vemurafenib after chemotherapy failed and achieved a satisfactory response. Furthermore, ALK-positive histiocytosis has shown responsiveness to ALK-targeted crizotinib.5Chang K.T.E. Tay A.Z.E. Kuick C.H. et al.ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion.Mod Pathol. 2019; 32: 598-608Abstract Full Text Full Text PDF PubMed Scopus (57) Google Scholar Limitations to our study include a small sample size and limited molecular alteration testing. Few patients with CJXG with suspected systemic involvement were radiologically examined. However, the recurrent ALK translocations detected in our study strongly suggest a novel mechanism of pathogenesis in SJXG. Molecular genetic analysis may improve precise diagnosis and management of this condition.